Global Spinal Muscular Atrophy Medicine Market Research Report 2025(Status and Outlook)
Report Overview
The global Spinal Muscular Atrophy Medicine market size was estimated at USD 6865.42 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.75% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Spinal Muscular Atrophy Medicine market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Spinal Muscular Atrophy Medicine market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Spinal Muscular Atrophy Medicine market
Global Spinal Muscular Atrophy Medicine Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Astellas Pharma Inc.
AveXisInc.
Bioblast Pharma Ltd.
CytokineticsInc. 24
F. Hoffmann-La Roche Ltd.
Genethon
Genzyme Corporation
GMP-Orphan SAS
Ionis PharmaceuticalsInc.
Longevity BiotechInc
Neurodyn Inc.
Neurotune AG
Novartis AG
Sarepta TherapeuticsInc.
Voyager TherapeuticsInc.
VybionInc.
WAVE Life Sciences Ltd.
Market Segmentation (by Type)
LMI-070
ND-602
NT-1654
Nusinersen
NXD-30001
Others
Market Segmentation (by Application)
Hospital
Clinic
Others
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Spinal Muscular Atrophy Medicine Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Spinal Muscular Atrophy Medicine, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
The global Spinal Muscular Atrophy Medicine market size was estimated at USD 6865.42 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.75% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Spinal Muscular Atrophy Medicine market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Spinal Muscular Atrophy Medicine market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Spinal Muscular Atrophy Medicine market
Global Spinal Muscular Atrophy Medicine Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Astellas Pharma Inc.
AveXisInc.
Bioblast Pharma Ltd.
CytokineticsInc. 24
F. Hoffmann-La Roche Ltd.
Genethon
Genzyme Corporation
GMP-Orphan SAS
Ionis PharmaceuticalsInc.
Longevity BiotechInc
Neurodyn Inc.
Neurotune AG
Novartis AG
Sarepta TherapeuticsInc.
Voyager TherapeuticsInc.
VybionInc.
WAVE Life Sciences Ltd.
Market Segmentation (by Type)
LMI-070
ND-602
NT-1654
Nusinersen
NXD-30001
Others
Market Segmentation (by Application)
Hospital
Clinic
Others
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Spinal Muscular Atrophy Medicine Market
- Overview of the regional outlook of the Spinal Muscular Atrophy Medicine Market.
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Spinal Muscular Atrophy Medicine Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Spinal Muscular Atrophy Medicine, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Spinal Muscular Atrophy Medicine
1.2 Key Market Segments
1.2.1 Spinal Muscular Atrophy Medicine Segment by Type
1.2.2 Spinal Muscular Atrophy Medicine Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 SPINAL MUSCULAR ATROPHY MEDICINE MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Spinal Muscular Atrophy Medicine Market Size (M USD) Estimates and Forecasts (2020-2033)
2.1.2 Global Spinal Muscular Atrophy Medicine Sales Estimates and Forecasts (2020-2033)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 SPINAL MUSCULAR ATROPHY MEDICINE MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Spinal Muscular Atrophy Medicine Product Life Cycle
3.3 Global Spinal Muscular Atrophy Medicine Sales by Manufacturers (2020-2025)
3.4 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Manufacturers (2020-2025)
3.5 Spinal Muscular Atrophy Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Spinal Muscular Atrophy Medicine Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Spinal Muscular Atrophy Medicine Market Competitive Situation and Trends
3.8.1 Spinal Muscular Atrophy Medicine Market Concentration Rate
3.8.2 Global 5 and 10 Largest Spinal Muscular Atrophy Medicine Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 SPINAL MUSCULAR ATROPHY MEDICINE INDUSTRY CHAIN ANALYSIS
4.1 Spinal Muscular Atrophy Medicine Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF SPINAL MUSCULAR ATROPHY MEDICINE MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Spinal Muscular Atrophy Medicine Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Spinal Muscular Atrophy Medicine Market
5.7 ESG Ratings of Leading Companies
6 SPINAL MUSCULAR ATROPHY MEDICINE MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2020-2025)
6.3 Global Spinal Muscular Atrophy Medicine Market Size Market Share by Type (2020-2025)
6.4 Global Spinal Muscular Atrophy Medicine Price by Type (2020-2025)
7 SPINAL MUSCULAR ATROPHY MEDICINE MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Spinal Muscular Atrophy Medicine Market Sales by Application (2020-2025)
7.3 Global Spinal Muscular Atrophy Medicine Market Size (M USD) by Application (2020-2025)
7.4 Global Spinal Muscular Atrophy Medicine Sales Growth Rate by Application (2020-2025)
8 SPINAL MUSCULAR ATROPHY MEDICINE MARKET SALES BY REGION
8.1 Global Spinal Muscular Atrophy Medicine Sales by Region
8.1.1 Global Spinal Muscular Atrophy Medicine Sales by Region
8.1.2 Global Spinal Muscular Atrophy Medicine Sales Market Share by Region
8.2 Global Spinal Muscular Atrophy Medicine Market Size by Region
8.2.1 Global Spinal Muscular Atrophy Medicine Market Size by Region
8.2.2 Global Spinal Muscular Atrophy Medicine Market Size Market Share by Region
8.3 North America
8.3.1 North America Spinal Muscular Atrophy Medicine Sales by Country
8.3.2 North America Spinal Muscular Atrophy Medicine Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Spinal Muscular Atrophy Medicine Sales by Country
8.4.2 Europe Spinal Muscular Atrophy Medicine Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Spinal Muscular Atrophy Medicine Sales by Region
8.5.2 Asia Pacific Spinal Muscular Atrophy Medicine Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Spinal Muscular Atrophy Medicine Sales by Country
8.6.2 South America Spinal Muscular Atrophy Medicine Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Region
8.7.2 Middle East and Africa Spinal Muscular Atrophy Medicine Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 SPINAL MUSCULAR ATROPHY MEDICINE MARKET PRODUCTION BY REGION
9.1 Global Production of Spinal Muscular Atrophy Medicine by Region(2020-2025)
9.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2020-2025)
9.3 Global Spinal Muscular Atrophy Medicine Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Spinal Muscular Atrophy Medicine Production
9.4.1 North America Spinal Muscular Atrophy Medicine Production Growth Rate (2020-2025)
9.4.2 North America Spinal Muscular Atrophy Medicine Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Spinal Muscular Atrophy Medicine Production
9.5.1 Europe Spinal Muscular Atrophy Medicine Production Growth Rate (2020-2025)
9.5.2 Europe Spinal Muscular Atrophy Medicine Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Spinal Muscular Atrophy Medicine Production (2020-2025)
9.6.1 Japan Spinal Muscular Atrophy Medicine Production Growth Rate (2020-2025)
9.6.2 Japan Spinal Muscular Atrophy Medicine Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Spinal Muscular Atrophy Medicine Production (2020-2025)
9.7.1 China Spinal Muscular Atrophy Medicine Production Growth Rate (2020-2025)
9.7.2 China Spinal Muscular Atrophy Medicine Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Astellas Pharma Inc.
10.1.1 Astellas Pharma Inc. Basic Information
10.1.2 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Overview
10.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Market Performance
10.1.4 Astellas Pharma Inc. Business Overview
10.1.5 Astellas Pharma Inc. SWOT Analysis
10.1.6 Astellas Pharma Inc. Recent Developments
10.2 AveXisInc.
10.2.1 AveXisInc. Basic Information
10.2.2 AveXisInc. Spinal Muscular Atrophy Medicine Product Overview
10.2.3 AveXisInc. Spinal Muscular Atrophy Medicine Product Market Performance
10.2.4 AveXisInc. Business Overview
10.2.5 AveXisInc. SWOT Analysis
10.2.6 AveXisInc. Recent Developments
10.3 Bioblast Pharma Ltd.
10.3.1 Bioblast Pharma Ltd. Basic Information
10.3.2 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Overview
10.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Market Performance
10.3.4 Bioblast Pharma Ltd. Business Overview
10.3.5 Bioblast Pharma Ltd. SWOT Analysis
10.3.6 Bioblast Pharma Ltd. Recent Developments
10.4 CytokineticsInc.
10.4.1 CytokineticsInc. 24 Basic Information
10.4.2 CytokineticsInc. 24 Spinal Muscular Atrophy Medicine Product Overview
10.4.3 CytokineticsInc. 24 Spinal Muscular Atrophy Medicine Product Market Performance
10.4.4 CytokineticsInc. 24 Business Overview
10.4.5 CytokineticsInc. 24 Recent Developments
10.5 F. Hoffmann-La Roche Ltd.
10.5.1 F. Hoffmann-La Roche Ltd. Basic Information
10.5.2 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Overview
10.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Market Performance
10.5.4 F. Hoffmann-La Roche Ltd. Business Overview
10.5.5 F. Hoffmann-La Roche Ltd. Recent Developments
10.6 Genethon
10.6.1 Genethon Basic Information
10.6.2 Genethon Spinal Muscular Atrophy Medicine Product Overview
10.6.3 Genethon Spinal Muscular Atrophy Medicine Product Market Performance
10.6.4 Genethon Business Overview
10.6.5 Genethon Recent Developments
10.7 Genzyme Corporation
10.7.1 Genzyme Corporation Basic Information
10.7.2 Genzyme Corporation Spinal Muscular Atrophy Medicine Product Overview
10.7.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Product Market Performance
10.7.4 Genzyme Corporation Business Overview
10.7.5 Genzyme Corporation Recent Developments
10.8 GMP-Orphan SAS
10.8.1 GMP-Orphan SAS Basic Information
10.8.2 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Overview
10.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Market Performance
10.8.4 GMP-Orphan SAS Business Overview
10.8.5 GMP-Orphan SAS Recent Developments
10.9 Ionis PharmaceuticalsInc.
10.9.1 Ionis PharmaceuticalsInc. Basic Information
10.9.2 Ionis PharmaceuticalsInc. Spinal Muscular Atrophy Medicine Product Overview
10.9.3 Ionis PharmaceuticalsInc. Spinal Muscular Atrophy Medicine Product Market Performance
10.9.4 Ionis PharmaceuticalsInc. Business Overview
10.9.5 Ionis PharmaceuticalsInc. Recent Developments
10.10 Longevity BiotechInc
10.10.1 Longevity BiotechInc Basic Information
10.10.2 Longevity BiotechInc Spinal Muscular Atrophy Medicine Product Overview
10.10.3 Longevity BiotechInc Spinal Muscular Atrophy Medicine Product Market Performance
10.10.4 Longevity BiotechInc Business Overview
10.10.5 Longevity BiotechInc Recent Developments
10.11 Neurodyn Inc.
10.11.1 Neurodyn Inc. Basic Information
10.11.2 Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Overview
10.11.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Market Performance
10.11.4 Neurodyn Inc. Business Overview
10.11.5 Neurodyn Inc. Recent Developments
10.12 Neurotune AG
10.12.1 Neurotune AG Basic Information
10.12.2 Neurotune AG Spinal Muscular Atrophy Medicine Product Overview
10.12.3 Neurotune AG Spinal Muscular Atrophy Medicine Product Market Performance
10.12.4 Neurotune AG Business Overview
10.12.5 Neurotune AG Recent Developments
10.13 Novartis AG
10.13.1 Novartis AG Basic Information
10.13.2 Novartis AG Spinal Muscular Atrophy Medicine Product Overview
10.13.3 Novartis AG Spinal Muscular Atrophy Medicine Product Market Performance
10.13.4 Novartis AG Business Overview
10.13.5 Novartis AG Recent Developments
10.14 Sarepta TherapeuticsInc.
10.14.1 Sarepta TherapeuticsInc. Basic Information
10.14.2 Sarepta TherapeuticsInc. Spinal Muscular Atrophy Medicine Product Overview
10.14.3 Sarepta TherapeuticsInc. Spinal Muscular Atrophy Medicine Product Market Performance
10.14.4 Sarepta TherapeuticsInc. Business Overview
10.14.5 Sarepta TherapeuticsInc. Recent Developments
10.15 Voyager TherapeuticsInc.
10.15.1 Voyager TherapeuticsInc. Basic Information
10.15.2 Voyager TherapeuticsInc. Spinal Muscular Atrophy Medicine Product Overview
10.15.3 Voyager TherapeuticsInc. Spinal Muscular Atrophy Medicine Product Market Performance
10.15.4 Voyager TherapeuticsInc. Business Overview
10.15.5 Voyager TherapeuticsInc. Recent Developments
10.16 VybionInc.
10.16.1 VybionInc. Basic Information
10.16.2 VybionInc. Spinal Muscular Atrophy Medicine Product Overview
10.16.3 VybionInc. Spinal Muscular Atrophy Medicine Product Market Performance
10.16.4 VybionInc. Business Overview
10.16.5 VybionInc. Recent Developments
10.17 WAVE Life Sciences Ltd.
10.17.1 WAVE Life Sciences Ltd. Basic Information
10.17.2 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Overview
10.17.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Market Performance
10.17.4 WAVE Life Sciences Ltd. Business Overview
10.17.5 WAVE Life Sciences Ltd. Recent Developments
11 SPINAL MUSCULAR ATROPHY MEDICINE MARKET FORECAST BY REGION
11.1 Global Spinal Muscular Atrophy Medicine Market Size Forecast
11.2 Global Spinal Muscular Atrophy Medicine Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Spinal Muscular Atrophy Medicine Market Size Forecast by Country
11.2.3 Asia Pacific Spinal Muscular Atrophy Medicine Market Size Forecast by Region
11.2.4 South America Spinal Muscular Atrophy Medicine Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Spinal Muscular Atrophy Medicine by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2033)
12.1 Global Spinal Muscular Atrophy Medicine Market Forecast by Type (2026-2033)
12.1.1 Global Forecasted Sales of Spinal Muscular Atrophy Medicine by Type (2026-2033)
12.1.2 Global Spinal Muscular Atrophy Medicine Market Size Forecast by Type (2026-2033)
12.1.3 Global Forecasted Price of Spinal Muscular Atrophy Medicine by Type (2026-2033)
12.2 Global Spinal Muscular Atrophy Medicine Market Forecast by Application (2026-2033)
12.2.1 Global Spinal Muscular Atrophy Medicine Sales (K MT) Forecast by Application
12.2.2 Global Spinal Muscular Atrophy Medicine Market Size (M USD) Forecast by Application (2026-2033)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Spinal Muscular Atrophy Medicine
1.2 Key Market Segments
1.2.1 Spinal Muscular Atrophy Medicine Segment by Type
1.2.2 Spinal Muscular Atrophy Medicine Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 SPINAL MUSCULAR ATROPHY MEDICINE MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Spinal Muscular Atrophy Medicine Market Size (M USD) Estimates and Forecasts (2020-2033)
2.1.2 Global Spinal Muscular Atrophy Medicine Sales Estimates and Forecasts (2020-2033)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 SPINAL MUSCULAR ATROPHY MEDICINE MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Spinal Muscular Atrophy Medicine Product Life Cycle
3.3 Global Spinal Muscular Atrophy Medicine Sales by Manufacturers (2020-2025)
3.4 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Manufacturers (2020-2025)
3.5 Spinal Muscular Atrophy Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Spinal Muscular Atrophy Medicine Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Spinal Muscular Atrophy Medicine Market Competitive Situation and Trends
3.8.1 Spinal Muscular Atrophy Medicine Market Concentration Rate
3.8.2 Global 5 and 10 Largest Spinal Muscular Atrophy Medicine Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 SPINAL MUSCULAR ATROPHY MEDICINE INDUSTRY CHAIN ANALYSIS
4.1 Spinal Muscular Atrophy Medicine Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF SPINAL MUSCULAR ATROPHY MEDICINE MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Spinal Muscular Atrophy Medicine Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Spinal Muscular Atrophy Medicine Market
5.7 ESG Ratings of Leading Companies
6 SPINAL MUSCULAR ATROPHY MEDICINE MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2020-2025)
6.3 Global Spinal Muscular Atrophy Medicine Market Size Market Share by Type (2020-2025)
6.4 Global Spinal Muscular Atrophy Medicine Price by Type (2020-2025)
7 SPINAL MUSCULAR ATROPHY MEDICINE MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Spinal Muscular Atrophy Medicine Market Sales by Application (2020-2025)
7.3 Global Spinal Muscular Atrophy Medicine Market Size (M USD) by Application (2020-2025)
7.4 Global Spinal Muscular Atrophy Medicine Sales Growth Rate by Application (2020-2025)
8 SPINAL MUSCULAR ATROPHY MEDICINE MARKET SALES BY REGION
8.1 Global Spinal Muscular Atrophy Medicine Sales by Region
8.1.1 Global Spinal Muscular Atrophy Medicine Sales by Region
8.1.2 Global Spinal Muscular Atrophy Medicine Sales Market Share by Region
8.2 Global Spinal Muscular Atrophy Medicine Market Size by Region
8.2.1 Global Spinal Muscular Atrophy Medicine Market Size by Region
8.2.2 Global Spinal Muscular Atrophy Medicine Market Size Market Share by Region
8.3 North America
8.3.1 North America Spinal Muscular Atrophy Medicine Sales by Country
8.3.2 North America Spinal Muscular Atrophy Medicine Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Spinal Muscular Atrophy Medicine Sales by Country
8.4.2 Europe Spinal Muscular Atrophy Medicine Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Spinal Muscular Atrophy Medicine Sales by Region
8.5.2 Asia Pacific Spinal Muscular Atrophy Medicine Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Spinal Muscular Atrophy Medicine Sales by Country
8.6.2 South America Spinal Muscular Atrophy Medicine Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Region
8.7.2 Middle East and Africa Spinal Muscular Atrophy Medicine Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 SPINAL MUSCULAR ATROPHY MEDICINE MARKET PRODUCTION BY REGION
9.1 Global Production of Spinal Muscular Atrophy Medicine by Region(2020-2025)
9.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2020-2025)
9.3 Global Spinal Muscular Atrophy Medicine Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Spinal Muscular Atrophy Medicine Production
9.4.1 North America Spinal Muscular Atrophy Medicine Production Growth Rate (2020-2025)
9.4.2 North America Spinal Muscular Atrophy Medicine Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Spinal Muscular Atrophy Medicine Production
9.5.1 Europe Spinal Muscular Atrophy Medicine Production Growth Rate (2020-2025)
9.5.2 Europe Spinal Muscular Atrophy Medicine Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Spinal Muscular Atrophy Medicine Production (2020-2025)
9.6.1 Japan Spinal Muscular Atrophy Medicine Production Growth Rate (2020-2025)
9.6.2 Japan Spinal Muscular Atrophy Medicine Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Spinal Muscular Atrophy Medicine Production (2020-2025)
9.7.1 China Spinal Muscular Atrophy Medicine Production Growth Rate (2020-2025)
9.7.2 China Spinal Muscular Atrophy Medicine Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Astellas Pharma Inc.
10.1.1 Astellas Pharma Inc. Basic Information
10.1.2 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Overview
10.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Market Performance
10.1.4 Astellas Pharma Inc. Business Overview
10.1.5 Astellas Pharma Inc. SWOT Analysis
10.1.6 Astellas Pharma Inc. Recent Developments
10.2 AveXisInc.
10.2.1 AveXisInc. Basic Information
10.2.2 AveXisInc. Spinal Muscular Atrophy Medicine Product Overview
10.2.3 AveXisInc. Spinal Muscular Atrophy Medicine Product Market Performance
10.2.4 AveXisInc. Business Overview
10.2.5 AveXisInc. SWOT Analysis
10.2.6 AveXisInc. Recent Developments
10.3 Bioblast Pharma Ltd.
10.3.1 Bioblast Pharma Ltd. Basic Information
10.3.2 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Overview
10.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Market Performance
10.3.4 Bioblast Pharma Ltd. Business Overview
10.3.5 Bioblast Pharma Ltd. SWOT Analysis
10.3.6 Bioblast Pharma Ltd. Recent Developments
10.4 CytokineticsInc.
10.4.1 CytokineticsInc. 24 Basic Information
10.4.2 CytokineticsInc. 24 Spinal Muscular Atrophy Medicine Product Overview
10.4.3 CytokineticsInc. 24 Spinal Muscular Atrophy Medicine Product Market Performance
10.4.4 CytokineticsInc. 24 Business Overview
10.4.5 CytokineticsInc. 24 Recent Developments
10.5 F. Hoffmann-La Roche Ltd.
10.5.1 F. Hoffmann-La Roche Ltd. Basic Information
10.5.2 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Overview
10.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Market Performance
10.5.4 F. Hoffmann-La Roche Ltd. Business Overview
10.5.5 F. Hoffmann-La Roche Ltd. Recent Developments
10.6 Genethon
10.6.1 Genethon Basic Information
10.6.2 Genethon Spinal Muscular Atrophy Medicine Product Overview
10.6.3 Genethon Spinal Muscular Atrophy Medicine Product Market Performance
10.6.4 Genethon Business Overview
10.6.5 Genethon Recent Developments
10.7 Genzyme Corporation
10.7.1 Genzyme Corporation Basic Information
10.7.2 Genzyme Corporation Spinal Muscular Atrophy Medicine Product Overview
10.7.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Product Market Performance
10.7.4 Genzyme Corporation Business Overview
10.7.5 Genzyme Corporation Recent Developments
10.8 GMP-Orphan SAS
10.8.1 GMP-Orphan SAS Basic Information
10.8.2 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Overview
10.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Market Performance
10.8.4 GMP-Orphan SAS Business Overview
10.8.5 GMP-Orphan SAS Recent Developments
10.9 Ionis PharmaceuticalsInc.
10.9.1 Ionis PharmaceuticalsInc. Basic Information
10.9.2 Ionis PharmaceuticalsInc. Spinal Muscular Atrophy Medicine Product Overview
10.9.3 Ionis PharmaceuticalsInc. Spinal Muscular Atrophy Medicine Product Market Performance
10.9.4 Ionis PharmaceuticalsInc. Business Overview
10.9.5 Ionis PharmaceuticalsInc. Recent Developments
10.10 Longevity BiotechInc
10.10.1 Longevity BiotechInc Basic Information
10.10.2 Longevity BiotechInc Spinal Muscular Atrophy Medicine Product Overview
10.10.3 Longevity BiotechInc Spinal Muscular Atrophy Medicine Product Market Performance
10.10.4 Longevity BiotechInc Business Overview
10.10.5 Longevity BiotechInc Recent Developments
10.11 Neurodyn Inc.
10.11.1 Neurodyn Inc. Basic Information
10.11.2 Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Overview
10.11.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Market Performance
10.11.4 Neurodyn Inc. Business Overview
10.11.5 Neurodyn Inc. Recent Developments
10.12 Neurotune AG
10.12.1 Neurotune AG Basic Information
10.12.2 Neurotune AG Spinal Muscular Atrophy Medicine Product Overview
10.12.3 Neurotune AG Spinal Muscular Atrophy Medicine Product Market Performance
10.12.4 Neurotune AG Business Overview
10.12.5 Neurotune AG Recent Developments
10.13 Novartis AG
10.13.1 Novartis AG Basic Information
10.13.2 Novartis AG Spinal Muscular Atrophy Medicine Product Overview
10.13.3 Novartis AG Spinal Muscular Atrophy Medicine Product Market Performance
10.13.4 Novartis AG Business Overview
10.13.5 Novartis AG Recent Developments
10.14 Sarepta TherapeuticsInc.
10.14.1 Sarepta TherapeuticsInc. Basic Information
10.14.2 Sarepta TherapeuticsInc. Spinal Muscular Atrophy Medicine Product Overview
10.14.3 Sarepta TherapeuticsInc. Spinal Muscular Atrophy Medicine Product Market Performance
10.14.4 Sarepta TherapeuticsInc. Business Overview
10.14.5 Sarepta TherapeuticsInc. Recent Developments
10.15 Voyager TherapeuticsInc.
10.15.1 Voyager TherapeuticsInc. Basic Information
10.15.2 Voyager TherapeuticsInc. Spinal Muscular Atrophy Medicine Product Overview
10.15.3 Voyager TherapeuticsInc. Spinal Muscular Atrophy Medicine Product Market Performance
10.15.4 Voyager TherapeuticsInc. Business Overview
10.15.5 Voyager TherapeuticsInc. Recent Developments
10.16 VybionInc.
10.16.1 VybionInc. Basic Information
10.16.2 VybionInc. Spinal Muscular Atrophy Medicine Product Overview
10.16.3 VybionInc. Spinal Muscular Atrophy Medicine Product Market Performance
10.16.4 VybionInc. Business Overview
10.16.5 VybionInc. Recent Developments
10.17 WAVE Life Sciences Ltd.
10.17.1 WAVE Life Sciences Ltd. Basic Information
10.17.2 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Overview
10.17.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Market Performance
10.17.4 WAVE Life Sciences Ltd. Business Overview
10.17.5 WAVE Life Sciences Ltd. Recent Developments
11 SPINAL MUSCULAR ATROPHY MEDICINE MARKET FORECAST BY REGION
11.1 Global Spinal Muscular Atrophy Medicine Market Size Forecast
11.2 Global Spinal Muscular Atrophy Medicine Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Spinal Muscular Atrophy Medicine Market Size Forecast by Country
11.2.3 Asia Pacific Spinal Muscular Atrophy Medicine Market Size Forecast by Region
11.2.4 South America Spinal Muscular Atrophy Medicine Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Spinal Muscular Atrophy Medicine by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2033)
12.1 Global Spinal Muscular Atrophy Medicine Market Forecast by Type (2026-2033)
12.1.1 Global Forecasted Sales of Spinal Muscular Atrophy Medicine by Type (2026-2033)
12.1.2 Global Spinal Muscular Atrophy Medicine Market Size Forecast by Type (2026-2033)
12.1.3 Global Forecasted Price of Spinal Muscular Atrophy Medicine by Type (2026-2033)
12.2 Global Spinal Muscular Atrophy Medicine Market Forecast by Application (2026-2033)
12.2.1 Global Spinal Muscular Atrophy Medicine Sales (K MT) Forecast by Application
12.2.2 Global Spinal Muscular Atrophy Medicine Market Size (M USD) Forecast by Application (2026-2033)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Spinal Muscular Atrophy Medicine Market Size Comparison by Region (M USD)
Table 5. Global Spinal Muscular Atrophy Medicine Sales (K MT) by Manufacturers (2020-2025)
Table 6. Global Spinal Muscular Atrophy Medicine Sales Market Share by Manufacturers (2020-2025)
Table 7. Global Spinal Muscular Atrophy Medicine Revenue (M USD) by Manufacturers (2020-2025)
Table 8. Global Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers (2020-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Spinal Muscular Atrophy Medicine as of 2024)
Table 10. Global Market Spinal Muscular Atrophy Medicine Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 11. Manufacturers? Manufacturing Sites, Areas Served
Table 12. Manufacturers? Product Type
Table 13. Global Spinal Muscular Atrophy Medicine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Market Overview of Key Raw Materials
Table 16. Midstream Market Analysis
Table 17. Downstream Customer Analysis
Table 18. Key Development Trends
Table 19. Driving Factors
Table 20. Spinal Muscular Atrophy Medicine Market Challenges
Table 21. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 22. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 23. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 24. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 25. Global Spinal Muscular Atrophy Medicine Sales by Type (K MT)
Table 26. Global Spinal Muscular Atrophy Medicine Market Size by Type (M USD)
Table 27. Global Spinal Muscular Atrophy Medicine Sales (K MT) by Type (2020-2025)
Table 28. Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2020-2025)
Table 29. Global Spinal Muscular Atrophy Medicine Market Size (M USD) by Type (2020-2025)
Table 30. Global Spinal Muscular Atrophy Medicine Market Size Share by Type (2020-2025)
Table 31. Global Spinal Muscular Atrophy Medicine Price (USD/KG) by Type (2020-2025)
Table 32. Global Spinal Muscular Atrophy Medicine Sales (K MT) by Application
Table 33. Global Spinal Muscular Atrophy Medicine Market Size by Application
Table 34. Global Spinal Muscular Atrophy Medicine Sales by Application (2020-2025) & (K MT)
Table 35. Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2020-2025)
Table 36. Global Spinal Muscular Atrophy Medicine Market Size by Application (2020-2025) & (M USD)
Table 37. Global Spinal Muscular Atrophy Medicine Market Share by Application (2020-2025)
Table 38. Global Spinal Muscular Atrophy Medicine Sales Growth Rate by Application (2020-2025)
Table 39. Global Spinal Muscular Atrophy Medicine Sales by Region (2020-2025) & (K MT)
Table 40. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2020-2025)
Table 41. Global Spinal Muscular Atrophy Medicine Market Size by Region (2020-2025) & (M USD)
Table 42. Global Spinal Muscular Atrophy Medicine Market Size Market Share by Region (2020-2025)
Table 43. North America Spinal Muscular Atrophy Medicine Sales by Country (2020-2025) & (K MT)
Table 44. North America Spinal Muscular Atrophy Medicine Market Size by Country (2020-2025) & (M USD)
Table 45. Europe Spinal Muscular Atrophy Medicine Sales by Country (2020-2025) & (K MT)
Table 46. Europe Spinal Muscular Atrophy Medicine Market Size by Country (2020-2025) & (M USD)
Table 47. Asia Pacific Spinal Muscular Atrophy Medicine Sales by Region (2020-2025) & (K MT)
Table 48. Asia Pacific Spinal Muscular Atrophy Medicine Market Size by Region (2020-2025) & (M USD)
Table 49. South America Spinal Muscular Atrophy Medicine Sales by Country (2020-2025) & (K MT)
Table 50. South America Spinal Muscular Atrophy Medicine Market Size by Country (2020-2025) & (M USD)
Table 51. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Region (2020-2025) & (K MT)
Table 52. Middle East and Africa Spinal Muscular Atrophy Medicine Market Size by Region (2020-2025) & (M USD)
Table 53. Global Spinal Muscular Atrophy Medicine Production (K MT) by Region(2020-2025)
Table 54. Global Spinal Muscular Atrophy Medicine Revenue (US$ Million) by Region (2020-2025)
Table 55. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2020-2025)
Table 56. Global Spinal Muscular Atrophy Medicine Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 57. North America Spinal Muscular Atrophy Medicine Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. Europe Spinal Muscular Atrophy Medicine Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Japan Spinal Muscular Atrophy Medicine Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. China Spinal Muscular Atrophy Medicine Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. Astellas Pharma Inc. Basic Information
Table 62. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Overview
Table 63. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 64. Astellas Pharma Inc. Business Overview
Table 65. Astellas Pharma Inc. SWOT Analysis
Table 66. Astellas Pharma Inc. Recent Developments
Table 67. AveXisInc. Basic Information
Table 68. AveXisInc. Spinal Muscular Atrophy Medicine Product Overview
Table 69. AveXisInc. Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 70. AveXisInc. Business Overview
Table 71. AveXisInc. SWOT Analysis
Table 72. AveXisInc. Recent Developments
Table 73. Bioblast Pharma Ltd. Basic Information
Table 74. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Overview
Table 75. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 76. Bioblast Pharma Ltd. Business Overview
Table 77. Bioblast Pharma Ltd. SWOT Analysis
Table 78. Bioblast Pharma Ltd. Recent Developments
Table 79. CytokineticsInc. 24 Basic Information
Table 80. CytokineticsInc. 24 Spinal Muscular Atrophy Medicine Product Overview
Table 81. CytokineticsInc. 24 Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 82. CytokineticsInc. 24 Business Overview
Table 83. CytokineticsInc. 24 Recent Developments
Table 84. F. Hoffmann-La Roche Ltd. Basic Information
Table 85. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Overview
Table 86. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 87. F. Hoffmann-La Roche Ltd. Business Overview
Table 88. F. Hoffmann-La Roche Ltd. Recent Developments
Table 89. Genethon Basic Information
Table 90. Genethon Spinal Muscular Atrophy Medicine Product Overview
Table 91. Genethon Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 92. Genethon Business Overview
Table 93. Genethon Recent Developments
Table 94. Genzyme Corporation Basic Information
Table 95. Genzyme Corporation Spinal Muscular Atrophy Medicine Product Overview
Table 96. Genzyme Corporation Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 97. Genzyme Corporation Business Overview
Table 98. Genzyme Corporation Recent Developments
Table 99. GMP-Orphan SAS Basic Information
Table 100. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Overview
Table 101. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 102. GMP-Orphan SAS Business Overview
Table 103. GMP-Orphan SAS Recent Developments
Table 104. Ionis PharmaceuticalsInc. Basic Information
Table 105. Ionis PharmaceuticalsInc. Spinal Muscular Atrophy Medicine Product Overview
Table 106. Ionis PharmaceuticalsInc. Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 107. Ionis PharmaceuticalsInc. Business Overview
Table 108. Ionis PharmaceuticalsInc. Recent Developments
Table 109. Longevity BiotechInc Basic Information
Table 110. Longevity BiotechInc Spinal Muscular Atrophy Medicine Product Overview
Table 111. Longevity BiotechInc Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 112. Longevity BiotechInc Business Overview
Table 113. Longevity BiotechInc Recent Developments
Table 114. Neurodyn Inc. Basic Information
Table 115. Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Overview
Table 116. Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 117. Neurodyn Inc. Business Overview
Table 118. Neurodyn Inc. Recent Developments
Table 119. Neurotune AG Basic Information
Table 120. Neurotune AG Spinal Muscular Atrophy Medicine Product Overview
Table 121. Neurotune AG Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 122. Neurotune AG Business Overview
Table 123. Neurotune AG Recent Developments
Table 124. Novartis AG Basic Information
Table 125. Novartis AG Spinal Muscular Atrophy Medicine Product Overview
Table 126. Novartis AG Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 127. Novartis AG Business Overview
Table 128. Novartis AG Recent Developments
Table 129. Sarepta TherapeuticsInc. Basic Information
Table 130. Sarepta TherapeuticsInc. Spinal Muscular Atrophy Medicine Product Overview
Table 131. Sarepta TherapeuticsInc. Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 132. Sarepta TherapeuticsInc. Business Overview
Table 133. Sarepta TherapeuticsInc. Recent Developments
Table 134. Voyager TherapeuticsInc. Basic Information
Table 135. Voyager TherapeuticsInc. Spinal Muscular Atrophy Medicine Product Overview
Table 136. Voyager TherapeuticsInc. Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 137. Voyager TherapeuticsInc. Business Overview
Table 138. Voyager TherapeuticsInc. Recent Developments
Table 139. VybionInc. Basic Information
Table 140. VybionInc. Spinal Muscular Atrophy Medicine Product Overview
Table 141. VybionInc. Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 142. VybionInc. Business Overview
Table 143. VybionInc. Recent Developments
Table 144. WAVE Life Sciences Ltd. Basic Information
Table 145. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Overview
Table 146. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 147. WAVE Life Sciences Ltd. Business Overview
Table 148. WAVE Life Sciences Ltd. Recent Developments
Table 149. Global Spinal Muscular Atrophy Medicine Sales Forecast by Region (2026-2033) & (K MT)
Table 150. Global Spinal Muscular Atrophy Medicine Market Size Forecast by Region (2026-2033) & (M USD)
Table 151. North America Spinal Muscular Atrophy Medicine Sales Forecast by Country (2026-2033) & (K MT)
Table 152. North America Spinal Muscular Atrophy Medicine Market Size Forecast by Country (2026-2033) & (M USD)
Table 153. Europe Spinal Muscular Atrophy Medicine Sales Forecast by Country (2026-2033) & (K MT)
Table 154. Europe Spinal Muscular Atrophy Medicine Market Size Forecast by Country (2026-2033) & (M USD)
Table 155. Asia Pacific Spinal Muscular Atrophy Medicine Sales Forecast by Region (2026-2033) & (K MT)
Table 156. Asia Pacific Spinal Muscular Atrophy Medicine Market Size Forecast by Region (2026-2033) & (M USD)
Table 157. South America Spinal Muscular Atrophy Medicine Sales Forecast by Country (2026-2033) & (K MT)
Table 158. South America Spinal Muscular Atrophy Medicine Market Size Forecast by Country (2026-2033) & (M USD)
Table 159. Middle East and Africa Spinal Muscular Atrophy Medicine Sales Forecast by Country (2026-2033) & (Units)
Table 160. Middle East and Africa Spinal Muscular Atrophy Medicine Market Size Forecast by Country (2026-2033) & (M USD)
Table 161. Global Spinal Muscular Atrophy Medicine Sales Forecast by Type (2026-2033) & (K MT)
Table 162. Global Spinal Muscular Atrophy Medicine Market Size Forecast by Type (2026-2033) & (M USD)
Table 163. Global Spinal Muscular Atrophy Medicine Price Forecast by Type (2026-2033) & (USD/KG)
Table 164. Global Spinal Muscular Atrophy Medicine Sales (K MT) Forecast by Application (2026-2033)
Table 165. Global Spinal Muscular Atrophy Medicine Market Size Forecast by Application (2026-2033) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Spinal Muscular Atrophy Medicine Market Size Comparison by Region (M USD)
Table 5. Global Spinal Muscular Atrophy Medicine Sales (K MT) by Manufacturers (2020-2025)
Table 6. Global Spinal Muscular Atrophy Medicine Sales Market Share by Manufacturers (2020-2025)
Table 7. Global Spinal Muscular Atrophy Medicine Revenue (M USD) by Manufacturers (2020-2025)
Table 8. Global Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers (2020-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Spinal Muscular Atrophy Medicine as of 2024)
Table 10. Global Market Spinal Muscular Atrophy Medicine Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 11. Manufacturers? Manufacturing Sites, Areas Served
Table 12. Manufacturers? Product Type
Table 13. Global Spinal Muscular Atrophy Medicine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Market Overview of Key Raw Materials
Table 16. Midstream Market Analysis
Table 17. Downstream Customer Analysis
Table 18. Key Development Trends
Table 19. Driving Factors
Table 20. Spinal Muscular Atrophy Medicine Market Challenges
Table 21. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 22. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 23. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 24. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 25. Global Spinal Muscular Atrophy Medicine Sales by Type (K MT)
Table 26. Global Spinal Muscular Atrophy Medicine Market Size by Type (M USD)
Table 27. Global Spinal Muscular Atrophy Medicine Sales (K MT) by Type (2020-2025)
Table 28. Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2020-2025)
Table 29. Global Spinal Muscular Atrophy Medicine Market Size (M USD) by Type (2020-2025)
Table 30. Global Spinal Muscular Atrophy Medicine Market Size Share by Type (2020-2025)
Table 31. Global Spinal Muscular Atrophy Medicine Price (USD/KG) by Type (2020-2025)
Table 32. Global Spinal Muscular Atrophy Medicine Sales (K MT) by Application
Table 33. Global Spinal Muscular Atrophy Medicine Market Size by Application
Table 34. Global Spinal Muscular Atrophy Medicine Sales by Application (2020-2025) & (K MT)
Table 35. Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2020-2025)
Table 36. Global Spinal Muscular Atrophy Medicine Market Size by Application (2020-2025) & (M USD)
Table 37. Global Spinal Muscular Atrophy Medicine Market Share by Application (2020-2025)
Table 38. Global Spinal Muscular Atrophy Medicine Sales Growth Rate by Application (2020-2025)
Table 39. Global Spinal Muscular Atrophy Medicine Sales by Region (2020-2025) & (K MT)
Table 40. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2020-2025)
Table 41. Global Spinal Muscular Atrophy Medicine Market Size by Region (2020-2025) & (M USD)
Table 42. Global Spinal Muscular Atrophy Medicine Market Size Market Share by Region (2020-2025)
Table 43. North America Spinal Muscular Atrophy Medicine Sales by Country (2020-2025) & (K MT)
Table 44. North America Spinal Muscular Atrophy Medicine Market Size by Country (2020-2025) & (M USD)
Table 45. Europe Spinal Muscular Atrophy Medicine Sales by Country (2020-2025) & (K MT)
Table 46. Europe Spinal Muscular Atrophy Medicine Market Size by Country (2020-2025) & (M USD)
Table 47. Asia Pacific Spinal Muscular Atrophy Medicine Sales by Region (2020-2025) & (K MT)
Table 48. Asia Pacific Spinal Muscular Atrophy Medicine Market Size by Region (2020-2025) & (M USD)
Table 49. South America Spinal Muscular Atrophy Medicine Sales by Country (2020-2025) & (K MT)
Table 50. South America Spinal Muscular Atrophy Medicine Market Size by Country (2020-2025) & (M USD)
Table 51. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Region (2020-2025) & (K MT)
Table 52. Middle East and Africa Spinal Muscular Atrophy Medicine Market Size by Region (2020-2025) & (M USD)
Table 53. Global Spinal Muscular Atrophy Medicine Production (K MT) by Region(2020-2025)
Table 54. Global Spinal Muscular Atrophy Medicine Revenue (US$ Million) by Region (2020-2025)
Table 55. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2020-2025)
Table 56. Global Spinal Muscular Atrophy Medicine Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 57. North America Spinal Muscular Atrophy Medicine Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. Europe Spinal Muscular Atrophy Medicine Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Japan Spinal Muscular Atrophy Medicine Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. China Spinal Muscular Atrophy Medicine Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. Astellas Pharma Inc. Basic Information
Table 62. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Overview
Table 63. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 64. Astellas Pharma Inc. Business Overview
Table 65. Astellas Pharma Inc. SWOT Analysis
Table 66. Astellas Pharma Inc. Recent Developments
Table 67. AveXisInc. Basic Information
Table 68. AveXisInc. Spinal Muscular Atrophy Medicine Product Overview
Table 69. AveXisInc. Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 70. AveXisInc. Business Overview
Table 71. AveXisInc. SWOT Analysis
Table 72. AveXisInc. Recent Developments
Table 73. Bioblast Pharma Ltd. Basic Information
Table 74. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Overview
Table 75. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 76. Bioblast Pharma Ltd. Business Overview
Table 77. Bioblast Pharma Ltd. SWOT Analysis
Table 78. Bioblast Pharma Ltd. Recent Developments
Table 79. CytokineticsInc. 24 Basic Information
Table 80. CytokineticsInc. 24 Spinal Muscular Atrophy Medicine Product Overview
Table 81. CytokineticsInc. 24 Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 82. CytokineticsInc. 24 Business Overview
Table 83. CytokineticsInc. 24 Recent Developments
Table 84. F. Hoffmann-La Roche Ltd. Basic Information
Table 85. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Overview
Table 86. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 87. F. Hoffmann-La Roche Ltd. Business Overview
Table 88. F. Hoffmann-La Roche Ltd. Recent Developments
Table 89. Genethon Basic Information
Table 90. Genethon Spinal Muscular Atrophy Medicine Product Overview
Table 91. Genethon Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 92. Genethon Business Overview
Table 93. Genethon Recent Developments
Table 94. Genzyme Corporation Basic Information
Table 95. Genzyme Corporation Spinal Muscular Atrophy Medicine Product Overview
Table 96. Genzyme Corporation Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 97. Genzyme Corporation Business Overview
Table 98. Genzyme Corporation Recent Developments
Table 99. GMP-Orphan SAS Basic Information
Table 100. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Overview
Table 101. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 102. GMP-Orphan SAS Business Overview
Table 103. GMP-Orphan SAS Recent Developments
Table 104. Ionis PharmaceuticalsInc. Basic Information
Table 105. Ionis PharmaceuticalsInc. Spinal Muscular Atrophy Medicine Product Overview
Table 106. Ionis PharmaceuticalsInc. Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 107. Ionis PharmaceuticalsInc. Business Overview
Table 108. Ionis PharmaceuticalsInc. Recent Developments
Table 109. Longevity BiotechInc Basic Information
Table 110. Longevity BiotechInc Spinal Muscular Atrophy Medicine Product Overview
Table 111. Longevity BiotechInc Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 112. Longevity BiotechInc Business Overview
Table 113. Longevity BiotechInc Recent Developments
Table 114. Neurodyn Inc. Basic Information
Table 115. Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Overview
Table 116. Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 117. Neurodyn Inc. Business Overview
Table 118. Neurodyn Inc. Recent Developments
Table 119. Neurotune AG Basic Information
Table 120. Neurotune AG Spinal Muscular Atrophy Medicine Product Overview
Table 121. Neurotune AG Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 122. Neurotune AG Business Overview
Table 123. Neurotune AG Recent Developments
Table 124. Novartis AG Basic Information
Table 125. Novartis AG Spinal Muscular Atrophy Medicine Product Overview
Table 126. Novartis AG Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 127. Novartis AG Business Overview
Table 128. Novartis AG Recent Developments
Table 129. Sarepta TherapeuticsInc. Basic Information
Table 130. Sarepta TherapeuticsInc. Spinal Muscular Atrophy Medicine Product Overview
Table 131. Sarepta TherapeuticsInc. Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 132. Sarepta TherapeuticsInc. Business Overview
Table 133. Sarepta TherapeuticsInc. Recent Developments
Table 134. Voyager TherapeuticsInc. Basic Information
Table 135. Voyager TherapeuticsInc. Spinal Muscular Atrophy Medicine Product Overview
Table 136. Voyager TherapeuticsInc. Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 137. Voyager TherapeuticsInc. Business Overview
Table 138. Voyager TherapeuticsInc. Recent Developments
Table 139. VybionInc. Basic Information
Table 140. VybionInc. Spinal Muscular Atrophy Medicine Product Overview
Table 141. VybionInc. Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 142. VybionInc. Business Overview
Table 143. VybionInc. Recent Developments
Table 144. WAVE Life Sciences Ltd. Basic Information
Table 145. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Overview
Table 146. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 147. WAVE Life Sciences Ltd. Business Overview
Table 148. WAVE Life Sciences Ltd. Recent Developments
Table 149. Global Spinal Muscular Atrophy Medicine Sales Forecast by Region (2026-2033) & (K MT)
Table 150. Global Spinal Muscular Atrophy Medicine Market Size Forecast by Region (2026-2033) & (M USD)
Table 151. North America Spinal Muscular Atrophy Medicine Sales Forecast by Country (2026-2033) & (K MT)
Table 152. North America Spinal Muscular Atrophy Medicine Market Size Forecast by Country (2026-2033) & (M USD)
Table 153. Europe Spinal Muscular Atrophy Medicine Sales Forecast by Country (2026-2033) & (K MT)
Table 154. Europe Spinal Muscular Atrophy Medicine Market Size Forecast by Country (2026-2033) & (M USD)
Table 155. Asia Pacific Spinal Muscular Atrophy Medicine Sales Forecast by Region (2026-2033) & (K MT)
Table 156. Asia Pacific Spinal Muscular Atrophy Medicine Market Size Forecast by Region (2026-2033) & (M USD)
Table 157. South America Spinal Muscular Atrophy Medicine Sales Forecast by Country (2026-2033) & (K MT)
Table 158. South America Spinal Muscular Atrophy Medicine Market Size Forecast by Country (2026-2033) & (M USD)
Table 159. Middle East and Africa Spinal Muscular Atrophy Medicine Sales Forecast by Country (2026-2033) & (Units)
Table 160. Middle East and Africa Spinal Muscular Atrophy Medicine Market Size Forecast by Country (2026-2033) & (M USD)
Table 161. Global Spinal Muscular Atrophy Medicine Sales Forecast by Type (2026-2033) & (K MT)
Table 162. Global Spinal Muscular Atrophy Medicine Market Size Forecast by Type (2026-2033) & (M USD)
Table 163. Global Spinal Muscular Atrophy Medicine Price Forecast by Type (2026-2033) & (USD/KG)
Table 164. Global Spinal Muscular Atrophy Medicine Sales (K MT) Forecast by Application (2026-2033)
Table 165. Global Spinal Muscular Atrophy Medicine Market Size Forecast by Application (2026-2033) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Spinal Muscular Atrophy Medicine
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Spinal Muscular Atrophy Medicine Market Size (M USD), 2024-2033
Figure 5. Global Spinal Muscular Atrophy Medicine Market Size (M USD) (2020-2033)
Figure 6. Global Spinal Muscular Atrophy Medicine Sales (K MT) & (2020-2033)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Spinal Muscular Atrophy Medicine Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Spinal Muscular Atrophy Medicine Product Life Cycle
Figure 13. Spinal Muscular Atrophy Medicine Sales Share by Manufacturers in 2024
Figure 14. Global Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers in 2024
Figure 15. Spinal Muscular Atrophy Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024
Figure 16. Global Market Spinal Muscular Atrophy Medicine Average Price (USD/KG) of Key Manufacturers in 2024
Figure 17. The Global 5 and 10 Largest Players: Market Share by Spinal Muscular Atrophy Medicine Revenue in 2024
Figure 18. Industry Chain Map of Spinal Muscular Atrophy Medicine
Figure 19. Global Spinal Muscular Atrophy Medicine Market PEST Analysis
Figure 20. Global Spinal Muscular Atrophy Medicine Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Spinal Muscular Atrophy Medicine Market Share by Type
Figure 27. Sales Market Share of Spinal Muscular Atrophy Medicine by Type (2020-2025)
Figure 28. Sales Market Share of Spinal Muscular Atrophy Medicine by Type in 2024
Figure 29. Market Size Share of Spinal Muscular Atrophy Medicine by Type (2020-2025)
Figure 30. Market Size Share of Spinal Muscular Atrophy Medicine by Type in 2024
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Spinal Muscular Atrophy Medicine Market Share by Application
Figure 33. Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2020-2025)
Figure 34. Global Spinal Muscular Atrophy Medicine Sales Market Share by Application in 2024
Figure 35. Global Spinal Muscular Atrophy Medicine Market Share by Application (2020-2025)
Figure 36. Global Spinal Muscular Atrophy Medicine Market Share by Application in 2024
Figure 37. Global Spinal Muscular Atrophy Medicine Sales Growth Rate by Application (2020-2025)
Figure 38. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2020-2025)
Figure 39. Global Spinal Muscular Atrophy Medicine Market Size Market Share by Region (2020-2025)
Figure 40. North America Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Spinal Muscular Atrophy Medicine Sales Market Share by Country in 2024
Figure 43. North America Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Spinal Muscular Atrophy Medicine Market Size Market Share by Country in 2024
Figure 45. U.S. Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Spinal Muscular Atrophy Medicine Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Spinal Muscular Atrophy Medicine Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Spinal Muscular Atrophy Medicine Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Spinal Muscular Atrophy Medicine Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Country in 2024
Figure 53. Europe Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Spinal Muscular Atrophy Medicine Market Size Market Share by Country in 2024
Figure 55. Germany Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Spinal Muscular Atrophy Medicine Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Spinal Muscular Atrophy Medicine Sales Market Share by Region in 2024
Figure 67. Asia Pacific Spinal Muscular Atrophy Medicine Market Size Market Share by Region in 2024
Figure 68. China Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Spinal Muscular Atrophy Medicine Sales and Growth Rate (K MT)
Figure 79. South America Spinal Muscular Atrophy Medicine Sales Market Share by Country in 2024
Figure 80. South America Spinal Muscular Atrophy Medicine Market Size and Growth Rate (M USD)
Figure 81. South America Spinal Muscular Atrophy Medicine Market Size Market Share by Country in 2024
Figure 82. Brazil Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Spinal Muscular Atrophy Medicine Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Spinal Muscular Atrophy Medicine Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Spinal Muscular Atrophy Medicine Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Spinal Muscular Atrophy Medicine Market Size Market Share by Region in 2024
Figure 92. Saudi Arabia Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Spinal Muscular Atrophy Medicine Production Market Share by Region (2020-2025)
Figure 103. North America Spinal Muscular Atrophy Medicine Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Spinal Muscular Atrophy Medicine Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Spinal Muscular Atrophy Medicine Production (K MT) Growth Rate (2020-2025)
Figure 106. China Spinal Muscular Atrophy Medicine Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Spinal Muscular Atrophy Medicine Sales Forecast by Volume (2020-2033) & (K MT)
Figure 108. Global Spinal Muscular Atrophy Medicine Market Size Forecast by Value (2020-2033) & (M USD)
Figure 109. Global Spinal Muscular Atrophy Medicine Sales Market Share Forecast by Type (2026-2033)
Figure 110. Global Spinal Muscular Atrophy Medicine Market Share Forecast by Type (2026-2033)
Figure 111. Global Spinal Muscular Atrophy Medicine Sales Forecast by Application (2026-2033)
Figure 112. Global Spinal Muscular Atrophy Medicine Market Share Forecast by Application (2026-2033)
Figure 1. Product Picture of Spinal Muscular Atrophy Medicine
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Spinal Muscular Atrophy Medicine Market Size (M USD), 2024-2033
Figure 5. Global Spinal Muscular Atrophy Medicine Market Size (M USD) (2020-2033)
Figure 6. Global Spinal Muscular Atrophy Medicine Sales (K MT) & (2020-2033)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Spinal Muscular Atrophy Medicine Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Spinal Muscular Atrophy Medicine Product Life Cycle
Figure 13. Spinal Muscular Atrophy Medicine Sales Share by Manufacturers in 2024
Figure 14. Global Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers in 2024
Figure 15. Spinal Muscular Atrophy Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024
Figure 16. Global Market Spinal Muscular Atrophy Medicine Average Price (USD/KG) of Key Manufacturers in 2024
Figure 17. The Global 5 and 10 Largest Players: Market Share by Spinal Muscular Atrophy Medicine Revenue in 2024
Figure 18. Industry Chain Map of Spinal Muscular Atrophy Medicine
Figure 19. Global Spinal Muscular Atrophy Medicine Market PEST Analysis
Figure 20. Global Spinal Muscular Atrophy Medicine Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Spinal Muscular Atrophy Medicine Market Share by Type
Figure 27. Sales Market Share of Spinal Muscular Atrophy Medicine by Type (2020-2025)
Figure 28. Sales Market Share of Spinal Muscular Atrophy Medicine by Type in 2024
Figure 29. Market Size Share of Spinal Muscular Atrophy Medicine by Type (2020-2025)
Figure 30. Market Size Share of Spinal Muscular Atrophy Medicine by Type in 2024
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Spinal Muscular Atrophy Medicine Market Share by Application
Figure 33. Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2020-2025)
Figure 34. Global Spinal Muscular Atrophy Medicine Sales Market Share by Application in 2024
Figure 35. Global Spinal Muscular Atrophy Medicine Market Share by Application (2020-2025)
Figure 36. Global Spinal Muscular Atrophy Medicine Market Share by Application in 2024
Figure 37. Global Spinal Muscular Atrophy Medicine Sales Growth Rate by Application (2020-2025)
Figure 38. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2020-2025)
Figure 39. Global Spinal Muscular Atrophy Medicine Market Size Market Share by Region (2020-2025)
Figure 40. North America Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Spinal Muscular Atrophy Medicine Sales Market Share by Country in 2024
Figure 43. North America Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Spinal Muscular Atrophy Medicine Market Size Market Share by Country in 2024
Figure 45. U.S. Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Spinal Muscular Atrophy Medicine Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Spinal Muscular Atrophy Medicine Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Spinal Muscular Atrophy Medicine Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Spinal Muscular Atrophy Medicine Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Country in 2024
Figure 53. Europe Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Spinal Muscular Atrophy Medicine Market Size Market Share by Country in 2024
Figure 55. Germany Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Spinal Muscular Atrophy Medicine Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Spinal Muscular Atrophy Medicine Sales Market Share by Region in 2024
Figure 67. Asia Pacific Spinal Muscular Atrophy Medicine Market Size Market Share by Region in 2024
Figure 68. China Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Spinal Muscular Atrophy Medicine Sales and Growth Rate (K MT)
Figure 79. South America Spinal Muscular Atrophy Medicine Sales Market Share by Country in 2024
Figure 80. South America Spinal Muscular Atrophy Medicine Market Size and Growth Rate (M USD)
Figure 81. South America Spinal Muscular Atrophy Medicine Market Size Market Share by Country in 2024
Figure 82. Brazil Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Spinal Muscular Atrophy Medicine Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Spinal Muscular Atrophy Medicine Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Spinal Muscular Atrophy Medicine Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Spinal Muscular Atrophy Medicine Market Size Market Share by Region in 2024
Figure 92. Saudi Arabia Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Spinal Muscular Atrophy Medicine Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Spinal Muscular Atrophy Medicine Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Spinal Muscular Atrophy Medicine Production Market Share by Region (2020-2025)
Figure 103. North America Spinal Muscular Atrophy Medicine Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Spinal Muscular Atrophy Medicine Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Spinal Muscular Atrophy Medicine Production (K MT) Growth Rate (2020-2025)
Figure 106. China Spinal Muscular Atrophy Medicine Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Spinal Muscular Atrophy Medicine Sales Forecast by Volume (2020-2033) & (K MT)
Figure 108. Global Spinal Muscular Atrophy Medicine Market Size Forecast by Value (2020-2033) & (M USD)
Figure 109. Global Spinal Muscular Atrophy Medicine Sales Market Share Forecast by Type (2026-2033)
Figure 110. Global Spinal Muscular Atrophy Medicine Market Share Forecast by Type (2026-2033)
Figure 111. Global Spinal Muscular Atrophy Medicine Sales Forecast by Application (2026-2033)
Figure 112. Global Spinal Muscular Atrophy Medicine Market Share Forecast by Application (2026-2033)
